CMV-specific immuno-dyregulation in recurrent glioblastoma patients can be overcome with therapeutic vaccineation which is associated with tumor response and overall survival benefits in a Phase I/Iia study

Conference: 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Date: June 22, 2020